Liver Cancer Disparities in American Indian and Alaska Native Persons
Recruiting
Phase 2
Interventional Study
Hepatocellular Carcinoma
Cirrhosis, Liver
Hepatitis B
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 200 (estimated)
- Sponsor
- University of Washington · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Cirrhosis, any etiology, or chronic HBV infection
* High risk of HCC
* Age 18-75
* Competent to provide informed consent
Exclusion Criteria:
* Prior diagnosis of HCC
* Current suspicion of HCC
* Prior receipt of any organ transplantation
* Participation in another HCC screen…
Contacts